In , Ind-Swift Laboratories Ltd (Pharma - API) is outperforming Nifty 500 with +39.2% relative strength. Fundamentals: Weak. On a 4-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Apr 18, 2026
What: Viatris Partnership: ₹200-220 Cr
Impact: ₹200-220 Cr incremental revenue
“strengthening CDMO visibility through the FY27 accretive Viatris partnership... ₹200-220 Cr incremental revenue expected in FY27.”
What: Net Debt: Zero
Impact: Net Debt Free
“transformed the company into a Net Debt Free entity with a unified operational structure.”
What: Ethical Division GM: 76%
Impact: 250-300 BPS EBITDA expansion
“Supported by high-margin segments like Ethical (76% GM), Own-Brand (51% GM) and CMO (42% GM).”
What: Registered Products: 400+
“expanding our Own-Brand footprint in UAE and Central Asia with 400+ registered products.”
What: Dossier Filings: 400+
“400+ dossier filings by FY27 to build long-term IP-led revenue visibility.”
What: PAT growth of 22.6% QoQ
“This improvement in operational efficiency, translated to a 22.60% rise in Net Profit (PAT) quarter-over-quarter.”
Earnings deceleration risks from management commentary
Trigger: The business model is heavily dependent on maintaining approvals from UK-MHRA, TGA, and Health Canada.
Management view: Strengthening QA/QC systems to support CMO scale-up and dossier filings.
Monitor: regulatory
Trigger: Fluctuations in input costs for formulation manufacturing.
Management view: Focusing on backward-integrated, cost-efficient manufacturing.
Monitor: commodity
Key quotes from recent conference calls
“Topline CAGR 20-25%, scaling from ₹550 Cr to ₹1,200+ Cr by FY29. [Previous Topline Growth guidance]”
“CDMO to triple over 4 years (₹180 Cr to ₹550-600 Cr) driven by commercial scale-ups. [Previous CDMO Revenue guidance]”
“Commercial supplies begin in 2026, ₹200-220 Cr incremental revenue expected in FY27. [Initiative: Viatris Partnership]”
“Scaling field-force & distribution in UAE, Uzbekistan, West Africa to move from market entry → market dominance. [Initiative: Greenfield Expansion]”
Headline numbers from the latest earnings call
Revenue
₹177.1 Cr
Why: Revenue growth was driven by stable demand in the formulations platform and improved operational efficiency in the standalone business.
Total revenue reached ₹177.06 Cr in Q3 FY26, showing steady sequential growth from ₹168.30 Cr in Q2 FY26.
EBITDA
₹9.1 Cr
Why: Operating EBITDA increased due to a reduction in raw material and employee benefit expenses during the quarter.
Operating EBITDA grew 6.6% QoQ to ₹9.11 Cr, with margins expanding to 5.95% from 5.46% in the previous quarter.
PAT
₹10.7 Cr
Why: The sequential rise in net profit was driven by improved operational efficiency and lower finance costs during the quarter.
PAT rose to ₹10.74 Cr in Q3 FY26 from ₹8.76 Cr in Q2 FY26, reflecting strong sequential recovery.
Other Highlights
• Net Debt Free status achieved following the ₹1,650 Cr divestment of the API and CRAMS business.
• Operating EBITDA margin expanded by 48 BPS sequentially to 5.95% in Q3 FY26.
• Finance costs reduced significantly to ₹0.67 Cr in Q3 FY26 from ₹2.01 Cr in Q2 FY26.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Total Dossiers Filed
1,915+
Why: Extensive dossier pipeline supporting long-term growth in regulated markets.
Global Approvals Received
520+
Why: Success rate in obtaining registrations across 85+ countries.
Europe Revenue Share
53%
Why: Europe remains the primary export market for the Global Business Unit.
Ethical Division Gross Margin
76%
Why: High-margin, prescription-driven business marketed directly to doctors.
Own-Brand Gross Margin
51%
Why: Direct marketing of Ind-Swift branded products in emerging markets.
Annual Tablet Capacity
9 Billion
Why: High-volume output capable of supporting >₹10 Billion revenue reach.
R&D Scientist Count
60+
Why: Specialized team focused on Finished Dosage development.
Fexofenadine Revenue Share
22%
Why: Fexofenadine remains the largest revenue contributor in the export portfolio.
Forward-looking targets from management for FY29
OPM Guidance
2.5–3%
₹1,200+ Cr by FY29
REAFFIRMED
Guidance Changes
CDMO Revenue: ₹180 Cr → ₹550-600 Cr
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +23% | -19% | Stable |
| PAT (Net Profit) | -93% | -5% | Inflection Down |
| OPM | 12.0% | +1900 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Ind-Swift Laboratories Ltd's latest quarterly results (Mar 2026) show
Ind-Swift Laboratories Ltd's profit is declining with an inflecting downward trend.
Ind-Swift Laboratories Ltd's revenue growth trend is stable.
Ind-Swift Laboratories Ltd's operating margin is volatile.
Ind-Swift Laboratories Ltd's long-term compounding rates
Ind-Swift Laboratories Ltd's earnings growth is inflecting downward with improving on a sequential basis.
Ind-Swift Laboratories Ltd's trailing twelve month (TTM) performance
Ind-Swift Laboratories Ltd appears significantly overvalued based on our fair value analysis.
Ind-Swift Laboratories Ltd's current PE ratio is 35.3x.
Ind-Swift Laboratories Ltd's current PE is 35.3x.
Ind-Swift Laboratories Ltd's price-to-book ratio is 1.3x.
Ind-Swift Laboratories Ltd is rated Weak with a fundamental score of 34.46/100. This score is calculated from objective financial metrics
Ind-Swift Laboratories Ltd has a debt-to-equity ratio of N/A.
Ind-Swift Laboratories Ltd's return ratios over recent years
Ind-Swift Laboratories Ltd's operating cash flow is negative (FY2026).
Ind-Swift Laboratories Ltd currently does not pay a significant dividend (yield 0.00%).
Ind-Swift Laboratories Ltd's shareholding pattern (Mar 2026)
Ind-Swift Laboratories Ltd's promoter holding has decreased recently.
Ind-Swift Laboratories Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Ind-Swift Laboratories Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Ind-Swift Laboratories Ltd has 6 key growth catalysts identified from recent earnings analysis
Ind-Swift Laboratories Ltd has 2 key risks worth monitoring
In Q3 FY26, Ind-Swift Laboratories Ltd's management highlighted
Ind-Swift Laboratories Ltd's management has provided the following forward guidance for FY29
Ind-Swift Laboratories Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Ind-Swift Laboratories Ltd may be worth studying
Ind-Swift Laboratories Ltd investment thesis summary:
Ind-Swift Laboratories Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
